Methotrexate in advanced endometrial carcinoma. A Phase II trial of the Gynecologic Oncology Group

H. B. Muss, J. A. Blessing, K. D. Hatch, J. T. Soper, K. D. Webster, G. M. Kemp

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Thirty-three patients with advanced or metastatic endometrial carcinoma were entered in a Phase II trial utilizing methotrexate, 40 mg/m2 intravenously on a weekly basis. Almost all patients had prior total abdominal hysterectomy and almost two-thirds prior pelvic irradiation. No patient had prior chemotherapy. There was one complete and one partial response, for a complete and partial response rate of 6% (95% confidence intervals for a response of 1.7 to 19.6%). Toxicity was mild, with major adverse effects being nausea and vomiting and myelosuppression. One death may have been drug related. Methotrexate displays minimal clinical activity in patients with advanced or recurrent endometrial carcinoma who have received no prior chemotherapy.

Original languageEnglish (US)
Pages (from-to)61-63
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number1
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Methotrexate in advanced endometrial carcinoma. A Phase II trial of the Gynecologic Oncology Group'. Together they form a unique fingerprint.

  • Cite this